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Abstract
Background: Indian guidelines recommend routine referral for HIV testing of all tuberculosis (TB) patients in the nine states
with the highest HIV prevalence, and selective referral for testing elsewhere. We assessed the clinical impact and cost-
effectiveness of alternative HIV testing referral strategies among TB patients in India.
Methods and Findings: We utilized a computer model of HIV and TB disease to project outcomes for patients with active TB
in India. We compared life expectancy, cost, and cost-effectiveness for three HIV testing referral strategies: 1) selective
referral for HIV testing of those with increased HIV risk, 2) routine referral of patients in the nine highest HIV prevalence
states with selective referral elsewhere (current standard), and 3) routine referral of all patients for HIV testing. TB-related
data were from the World Health Organization. HIV prevalence among TB patients was 9.0% in the highest prevalence
states, 2.9% in the other states, and 4.9% overall. The selective referral strategy, beginning from age 33.50 years, had a
projected discounted life expectancy of 16.88 years and a mean lifetime HIV/TB treatment cost of US$100. The current
standard increased mean life expectancy to 16.90 years with additional per-person cost of US$10; the incremental cost-
effectiveness ratio was US$650/year of life saved (YLS) compared to selective referral. Routine referral of all patients for HIV
testing increased life expectancy to 16.91 years, with an incremental cost-effectiveness ratio of US$730/YLS compared to the
current standard. For HIV-infected patients cured of TB, receiving antiretroviral therapy increased survival from 4.71 to 13.87
years. Results were most sensitive to the HIV prevalence and the cost of second-line antiretroviral therapy.
Conclusions: Referral of all patients with active TB in India for HIV testing will be both effective and cost-effective. While
effective implementation of this strategy would require investment, routine, voluntary HIV testing of TB patients in India
should be recommended.
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Introduction
India accounts for one fifth of the global burden of tuberculosis
(TB), with 1.8 million new cases of active TB each year—more
new cases than any other country [1]. The Revised National
Tuberculosis Control Programme (RNTCP) in India reports that
two in five Indians are infected with latent TB [2]. India also has a
substantial burden of HIV; recent estimates from the World
Health Organization (WHO) and India’s National AIDS Control
Organization (NACO) report 2.5 million people living with HIV
in India (an overall population HIV prevalence of 0.36%) [2,3].
HIV co-infection substantially increases the risk of progression
from latent TB infection to active TB, and TB is the leading cause
of mortality in HIV-infected persons in India [1,4]. However,
recent studies have shown substantial improvement in CD4 counts
and decreased mortality among HIV-infected patients who
received ART during TB treatment compared to HIV-infected
patients without access to antiretrovirals [5,6].
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HIV disease by establishing cross-referral mechanisms between
facilities providing TB services and HIV integrated counseling and
testing centers [7]. NACO guidelines recommend that all patients
with active TB and HIV risk factors be referred for HIV
counseling and testing [7]. Yet current estimates show that less
than 6% of TB patients are tested for HIV infection [8]. In 2007,
the Indian government reported that over 12% of the 77,000 TB
patients referred for HIV testing were diagnosed with HIV [9].
National TB/HIV policy in India is evolving. In 2007, NACO and
the Central TB Division established the first National Framework
of Joint TB/HIV Collaborative Activities, expanding basic TB/
HIV activities to all states [7]. In October 2008, guidelines were
changed to implement an Intensified TB/HIV Package in the nine
states with the highest HIV prevalence, including referral to HIV
counseling and testing sites for HIV tests free of charge for all TB
patients, with continued selective referral in the other 26 states
[2,10]. The National Framework for Joint TB/HIV Collaborative
Activities was further revised in 2009 to establish uniform
guidelines at counseling and testing centers and ART centers
nationwide, to standardize monitoring and evaluation, and to
expand the Intensified TB/HIV Package to all states by 2012 [11].
The TB/HIV Collaborative Activities also include routine TB
screening for patients attending HIV testing centers and ART
centers; however, the current analysis addresses HIV testing
referral for TB patients. Our objective was to project the clinical
and economic outcomes of alternative referral strategies for HIV
testing among TB patients in India.
Methods
Analytic Overview
We use the Cost-Effectiveness of Preventing AIDS Complications
(CEPAC) International model, a state-transition simulation model of
HIV and TB disease in resource-limited settings, to project the life
expectancy, cost, and cost-effectiveness of HIV testing for patients
with active TBinIndia. Details ofthe model arepublished elsewhere
[12,13,14,15,16,17]. Input parameters for the model include data on
both TB and HIV natural history, treatment efficacy, and costs of
care from India; model outputs include projected per-person life
expectancy, lifetime cost, and cost-effectiveness. Life expectancy and
cost are discounted at 3% per year [18].
We estimate life expectancy and costs for three different HIV
testing referral strategies for TB patients: 1) selective referral of
patientsconsideredtobeathighriskforHIV,hereafterreferredtoas
‘‘selective referral,’’ 2) routine referral of patients in the nine highest
HIV prevalence states with selective referral in the other 26 states
(the ‘‘current standard’’), and 3) routine referral of all patients for
HIV testing, hereafter ‘‘routine referral.’’ Patients at ‘‘high-risk’’ for
HIV—those targeted for HIV testing under the ‘‘selective referral’’
strategy—include those who report a history of high-risk behavior,
who have a history of sexually transmitted infection, and/or who
have signs and symptoms suggestive of HIV-related opportunistic
infections [7]. For each HIV testing referral strategy, patients who
are referredfor HIV testing,offered a test,andaccepttesting,receive
one rapid HIV test; those with reactive tests receive a confirmatory
rapid test. For each strategy, the overall probability that a patient is
referred for HIV testing and receives the test is referred to as the
‘‘probability of offer/accept’’ [9,19]. There are three HIV testing-
related outcomes: 1) HIV-negative, 2) HIV-infected, but not tested
or linked to HIV care and therefore not treated, and 3) HIV-
infected, tested, linked to care, and treated (Figure S1). Patients with
HIV infection who are not tested initially enter HIV care later in the
course of disease, upon the occurrence of a severe opportunistic
infection (excluding bacterial infections and recurrent TB). HIV-
infected patients who are tested and linked to care, but not yet
eligible for antiretroviral therapy (CD4 count.350/ml), are
monitored with regular clinic visits every 3 months and receive
treatment for acute opportunistic infections. They also have CD4
counts every 6 months, and are initiated on antiretroviral therapy
(ART) once their CD4 count falls below 350/ml.
We were guided by the Commission on Macroeconomics and
Health, sponsored by the WHO, in determining if a particular
HIV testing strategy is considered ‘‘cost-effective.’’ Strategies with
incremental cost-effectiveness ratios ,3 times the per capita Gross
Domestic Product (GDP) in India (3x per capita GDP=$3,050) are
considered ‘‘cost-effective,’’ while strategies with incremental cost-
effectiveness ratios ,1 times the per capita GDP (1x per capita
GDP=$1,015) are considered ‘‘very cost-effective’’ [20,21].
Tuberculosis Disease States
The CEPAC International model incorporates detailed data
with respect to both TB and TB/HIV co-infection. There are five
mutually exclusive TB health states considered: no TB exposure,
latent TB infection, active TB disease without treatment, active
TB disease with treatment, and history of active TB. Patients
transition among health states if they experience a primary latent
or active TB infection, re-infection, relapse of an active infection,
or spontaneous resolution, or if they complete treatment
successfully or fail treatment. The four TB outcomes considered
are: cured, failed TB treatment, defaulted (TB treatment
interrupted for at least two consecutive months), or died.
HIV Disease and Treatment
The natural history of HIV disease is determined by CD4 count
decline, the rate of which depends on HIV RNA level [22]. HIV
morbidity and mortality are CD4 count-dependent, with higher
morbidity and mortality at lower CD4 counts [23]. ART reduces
HIV RNA levels, increases CD4 counts, and thus decreases HIV-
related morbidity and mortality [36]. Data on virologic efficacy
and CD4 count increases due to ART are from a published trial
[24]. ART regimens and treatment policies follow recommenda-
tions from NACO and the WHO [25,26]. First-line ART is a non-
nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen
consisting of nevirapine and two nucleoside reverse transcriptase
inhibitors (NRTIs), usually stavudine and lamivudine. HIV co-
infected patients in care have CD4 count tests every 6 months and
are treated with co-trimoxazole and two sequential ART regimens
once their CD4 count falls to ,350 cells/ml, per NACO guidelines
[25,27]. All TB-related outcomes are worse for HIV-infected
patients than for HIV-negative patients and for HIV-infected
patients who do not receive ART compared to those on ART [28].
All HIV-infected patients are subject to a monthly risk of mortality
from both TB and HIV.
Model Input Data
Cohort Characteristics. Baseline characteristics reflect the
composition of patients enrolled in a study of short-course anti-TB
treatment at the Tuberculosis Research Centre in Chennai, India
[29]. Mean age at initial HIV test is 33.50 years (SD 7.20 years),
and 83% are male (Table 1). The overall prevalence of HIV
disease in TB patients is 4.9% and among those with TB/HIV co-
infection, mean CD4 count is 169/ml (SD 126/ml) [29,30].
Additional cohort characteristics are shown in Table S1.
TB-related Data. The proportion of each TB treatment
outcome in the HIV-negative and HIV-infected patients is from
the WHO [31]. For HIV-negative patients at six months, 83% are
cured of TB, 3% fail TB treatment, 8% default from TB
HIV Testing of TB Patients
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HIV co-infection, at six months 61% are cured of TB, 3% fail TB
treatment, 14% default from TB treatment, and 22% die [31].
Mean survival and cost of each TB treatment outcome are
weighted according to the proportion of those outcomes as
reported by WHO to determine the overall survival and cost for
the simulated cohort (Table 1; Tables S2, S3, S4). Mortality rates
for each TB outcome are midpoint assumptions on survival for
HIV-negative TB patients in India (Table 2).
HIV Disease and Treatment. Data on HIV natural history
are from the Y.R. Gaitonde Center for AIDS Research and
Education (YRG CARE) in Chennai, India [23]. The efficacy of a
Table 1. Baseline cohort characteristics, TB treatment outcomes, and model inputs for an analysis of HIV testing for TB patients in
India.
Variable Base case input Range used in sensitivity analyses Reference
Cohort Characteristics
Age, years (SD) 33.5 (7.2) 25.0–45.0 [29]
Male/Female (%) 83/17 [29]
HIV prevalence among TB patients (%) 4.9 0.0–10.0 [30]
Mean CD4 count at HIV diagnosis, cells/ml (SD) 169 (126) 85–335 [29]
TB Treatment Outcome (at 1 year from TB diagnosis)
{
HIV-negative population, % within each subgroup [31]
Cured 83 73–93
Failed TB treatment 3 1–6
Defaulted on TB treatment 8 4–12
Died 6 3–9
HIV-infected population, % within each subgroup [31]
Cured 61 51–71
Failed TB treatment 3 1–6
Defaulted on TB treatment 14 9–19
Died 22 17–27
SD: Standard deviation; TB: Tuberculosis.
{Cured: smear-negative in the last month of treatment; Failed: Remained smear-positive at month 5 or later during TB treatment; Defaulted: TB treatment was
interrupted for at least 2 consecutive months; Died: Died from any cause during TB treatment [31].
doi:10.1371/journal.pone.0012747.t001
Table 2. TB mortality and ART efficacy model inputs for an analysis of HIV testing for TB patients in India.
Variable Base case input Range used in sensitivity analyses Reference
Mortality from 1–3 years following TB diagnosis, according to HIV serostatus and TB treatment outcome subgroup (%)
HIV-negative
Cured 6 3–12 [59]
Failed TB treatment 34 17–68 [59]
Defaulted on TB treatment 42 21–84 [59]
HIV-infected, untreated for HIV
Cured 37 19–74 [29]
Failed TB treatment 68 34–95 Assumption*
Defaulted on TB treatment 84 42–95 Assumption*
HIV-infected, treated (ART)
Cured 10 5–20 Assumption*
Failed TB treatment 50 25–75 Assumption*
Defaulted on TB treatment 84 42–95 Assumption*
Efficacy of antiretroviral therapy
HIV RNA suppression at 24 weeks (%) 73 60–90 [24]
CD4 count increase at 24 weeks (cells/ml) 148 100–200 [32]
ART: antiretroviral therapy; TB: Tuberculosis.
*Assumed 67% of mortality occurred in months 12–18 and 33% occurred in months 19–36. See Text S1 for further details on extended mortality.
doi:10.1371/journal.pone.0012747.t002
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suppression (HIV RNA ,50 copies/ml) at 24 weeks with a
mean CD4 increase of 148/ml at 24 weeks (Table 2) [24,32].
Second-line ART, consisting of ritonavir-boosted lopinavir,
zidovudine and emtricitabine, was assumed to have similar
efficacy as first-line ART. Additional details on the clinical input
data have been published elsewhere [12,13,33].
HIV Testing Offer/Acceptance and Outcomes. Selective
referral (Strategy 1) has a test offer/accept probability of 5.2% and
detects 13.2% of those with HIV (Table 3) [9]. The current
standard (routine referral in the nine highest HIV prevalence
states, with selective referral elsewhere; Strategy 2), has a test
offer/accept probability of 22.7% and detects 44.7% of those with
HIV. Routine referral for all TB patients (Strategy 3) has a test
offer/accept probability of 66.2% and detects 66.2% of those with
HIV [9,19]. The Technical Appendix (Text S1) contains a
detailed description of calculations for HIV test offer/accept and
the proportion of HIV among TB patients detected. Of ART-
eligible patients newly identified as HIV-infected under Strategy 3,
26.0% link to HIV care, defined as starting ART if eligible [19].
We assumed the same linkage to care rates for Strategies 1 and 2,
but varied this assumption in sensitivity analysis.
Costs of Testing and Care. Resource utilization data are
from the YRG CARE database, as well as from a daily cost analysis
of YRG CARE conducted by Family Health International [34].
Input parameters include the number of inpatient and outpatient
days associated with routine HIV care, acute HIV-associated
opportunistic infections, and death. ART drug costs are from
India’s National AIDS Control Organisation [35]. Annual per-
person costs of first- and second-line ART are $108 and $690, and
the annual cost of co-trimoxazole prophylaxis is $4 (Table 4)
[35,36]. The cost of TB treatment, consisting of ethambutol,
isoniazid, rifampicin and pyrazinamide three times weekly for two
months, followed by rifampicin and isoniazid three times weekly for
four months, is $34 [37]. The cost of an HIV test is $3, including the
salary of the counselor but excluding infrastructure costs related to
scale-up of HIV testing [38]. All costs are standardized to 2008 US
dollars using India’s 2008 GDP deflator [21].
Sensitivity Analyses. Univariate sensitivity analyses are
performed on key model parameters to assess how changes in
these parameters affect the results. We also performed two-way
sensitivity analyses on parameters with the greatest impact on the
results. HIV-related parameters examined include HIV
prevalence, percent of patients tested for HIV, linkage to HIV
care after a positive HIV test, and HIV test cost. ART parameters
examined in sensitivity analyses include efficacy, availability, and
cost of both first- and second-line ART, and TB parameters
examined include TB treatment outcomes, rates of TB mortality
and cost of TB treatment.
Results
Survival and Cost for HIV-Negative and HIV-Infected
Patients
Among HIV-negative patients, those who were cured of TB,
failed TB treatment, or defaulted, had mean undiscounted life
expectancies, beginning at age 33.50, ranging from 33.89 years
down to 18.38 years (Table 5). Mean per person lifetime TB-
related costs ranged from $20–$75.
TB patients who were HIV-infected, but not tested or treated
for HIV, and who survived 6 months with TB, had projected
undiscounted mean life expectancies ranging from 1.33 years to
4.71 years, and costs ranging from $440-$1,990, depending on
their TB outcomes. For those tested and treated for HIV, both
mean undiscounted life expectancy and lifetime costs increased
substantially compared to those with untreated HIV. HIV-infected
patients on ART who survived 6 months with TB had projected
life expectancies ranging from 2.03 years to 13.87 years,
depending on TB outcomes. Lifetime costs for those tested and
treated for HIV and who survived 6 months with TB, ranged from
Table 3. Rates of HIV test offer and acceptance, proportion of HIV/TB co-infection detected, and linkage to HIV care, stratified by
referral strategy, for TB patients in India.
Parameter Strategy 1: Selective referral
Strategy 2: Routine referral in 9 states
with high HIV prevalence
Strategy 3: Routine referral in
all states
Data Source Data Source Data Source
Total # of TB patients registered
for treatment
1,475,587 RNTCP[9] 1,475,587 RNTCP[9] 1,475,587 RNTCP[9]
Probability of HIV test offer/accept 5.2% RNTCP[9] 22.7% RNTCP[9] Vijay,
et al.[19]
66.2% Vijay, et al.[19]
# of TB patients tested for HIV 77,000 RNTCP[9] 335,460 Calculation
¥ 976,839 Calculation
¥
HIV prevalence in TB patients
tested for HIV
12.3% RNTCP[9] 9.0% (high prev. states),
12.3% (other states)
Calculation
¥ 4.85% Calculation
¥
Actual HIV prevalence in TB
patient population
4.85% across all
TB patients
RNTCP[2] 9.0%
1 (high prev. states),
2.9%
{ (other states)
Raizada et al.[10] 4.85% across all
TB patients
RNTCP[2]
Proportion of HIV-TB co-infection
detected
13.2% Calculation
¥ 44.7% Calculation
¥ 66.2% Calculation
¥
Probability of linkage to HIV care* 26% Vijay, et al.[19]2 6 % Vijay, et al.[19] 26% Vijay, et al.[19]
RNTCP: Revised National Tuberculosis Control Programme [9].
1Average HIV seroprevalence among TB patients in the districts in the 4 high prevalence states included in Raizada 2008: Andhra Pradesh, Karnataka, Maharashtra, Tamil
Nadu [10].
{Average HIV seroprevalence among TB patients in all districts in the 4 low prevalence states included in Raizada 2008: Junagadh and Vadodara, Gujarat; Thrissur, Kerala;
Jodhpur, Rajasthan; Koch Bihar and Uttar Dinajpur, West Bengal [10].
¥See Text S1 for a detailed description of calculations.
*Linkage to HIV care is defined as the percent of TB patients starting ART for those determined to be ART-eligible. Probability for Strategies 1 and 2 assumed similar to
Strategy 3 [19].
doi:10.1371/journal.pone.0012747.t003
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treated for HIV had a projected mean life expectancy of 9.04
years, compared to 3.21 years for those HIV-infected but not
treated for HIV.
Base Case Analysis
The mean life expectancy and costs for each of the 12 subgroups
of TB and HIV patients were weighted by the frequency of their
occurrence to determine the overall projected mean life expec-
tancy and cost for each HIV testing referral strategy (Tables S2,
S3, S4). For Strategy 1 (selective referral), discounted mean life
expectancy was projected to be 16.88 years with a mean
discounted lifetime cost of $100 (Table 6). Strategy 2 increased
survival by 0.02 years at an additional cost of $10, for an
incremental cost-effectiveness ratio of $650/year of life saved
(YLS) compared to Strategy 1. Strategy 3 (routine referral), further
increased discounted life expectancy by 0.01 years and costs by
$10 compared to Strategy 2, with an incremental cost-effectiveness
ratio of $730/YLS.
Sensitivity Analyses
Sensitivity analyses showed that results were most sensitive to
the prevalence of HIV in patients receiving TB treatment.
However, until the prevalence dropped below 0.5%, substantially
below the reported HIV prevalence among TB patients in any
setting in India, the cost-effectiveness ratio for Strategy 3 (routine
referral) remained less than 3x the per capita GDP in India, $3,050/
YLS (Figure 1). In multivariate sensitivity analysis, we varied HIV
test cost simultaneously with HIV prevalence; even if the HIV test
cost was increased 10-fold, to $30/test, Strategy 3 still had a cost-
effectiveness ratio below $3,050/YLS, unless the HIV prevalence
among TB patients was also less than 2.5% (Figure 1, dotted line).
Although TB treatment outcomes affected projected survival
substantially, they did not have an important effect on cost-
effectiveness results. If the proportion of patients cured of TB
increased an absolute 10%—to 93% for HIV-negative patients
and to 71% for HIV-infected patients—and the proportion of
patients defaulting, failing treatment, or dying decreased, the
projected life expectancy for Strategy 2 increased from 16.90 years
Table 4. Cost inputs for an analysis of HIV testing for TB patients in India.
Variable Base case input Range used in sensitivity analyses Reference
Costs (2008 US$)
First-line ART, yearly
1 108 36–180 [35]
Second-line ART, yearly
1 690 300–1,200 [35]
Co-trimoxazole prophylaxis, yearly 4 4–11 [36]
TB treatment
¥ 34 10–100 [37]
HIV test cost 3 3–30
ART: antiretroviral therapy; TB: Tuberculosis.
1First-line ART: non-nucleoside reverse transcriptase inhibitor-based regimen; Second-line ART: protease inhibitor-based regimen (See Methods for details).
¥Cost of TB treatment includes personnel costs, cost of the drug regimen, and cost of a sputum smear and chest x-ray [37].
doi:10.1371/journal.pone.0012747.t004
Table 5. Life expectancy and cost outcomes for groups of TB patients in India, stratified by HIV infection and treatment status.
TB outcome according to HIV serostatus Outcome frequency (%) Undiscounted life expectancy (years) Lifetime cost (US$)
1
HIV-negative
Cured 83 33.89 75
Failed TB treatment 3 21.60 45
Defaulted on TB treatment 8 18.38 20
Died 6 0.37 40
HIV-infected, untreated for HIV
¥
Cured 61 4.71 1,990
Failed TB treatment 3 2.57 1,035
Defaulted on TB treatment 14 1.33 440
Died 22 0.35 55
HIV-infected, treated with antiretroviral therapy*
Cured 61 13.87 7,840
Failed TB treatment 3 7.05 3,875
Defaulted on TB treatment 14 2.03 985
Died 22 0.36 135
1Costs include $12 end of life care cost and opportunistic infection treatment costs, but do not include $3 HIV test cost. Costs are in 2008 US$.
¥HIV-infected, untreated for HIV still receive treatment for acute opportunistic infections.
*Per Indian guidelines [25].
doi:10.1371/journal.pone.0012747.t005
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from 16.91 years to 18.08 years. The cost-effectiveness of Strategy
3 compared to Strategy 2 decreased to $720/YLS. If the
proportion of patients cured of TB decreased an absolute
10%—to 73% for HIV-negative patients and to 51% for HIV-
infected patients—and the proportion of other TB outcomes
increased, the projected life expectancy decreased to 15.83 years
for Strategy 2 and 15.84 years for Strategy 3, while the cost-
effectiveness ratio of Strategy 3 compared to Strategy 2 increased
to $760/YLS. We also decreased the rates of death to 13% for
HIV-infected patients not receiving ART and 8% for HIV-
infected patients receiving ART to match the results of a recent
meta-analysis by Khan et al. on TB treatment among HIV-infected
patients [39]. This change did not affect the policy results.
The cost of second-line ART had an important impact on the
cost-effectiveness results. As costs decreased from the baseline of
$690/year, HIV testing in all strategies became more cost-
effective. Decreasing the cost of second-line ART to $300/year,
the cost-effectiveness ratio of Strategy 3 compared to Strategy 2
improved from $730/YLS to $350/YLS. Increasing the cost of
second-line ART to $1,200/year increased the cost-effectiveness
ratio of Strategy 3 to $950/YLS. If second-line ART was not
available, then routine referral for HIV testing led to lower life
expectancy, but its cost-effectiveness ratio was $430/YLS, still less
than 1x the per capita GDP in India.
Results were not sensitive to initial age, CD4 count at diagnosis,
TB mortality rates, rates of virologic suppression on first- or
second-line ART, cost of TB treatment, or HIV test cost. The
rates of test offer/accept and linkage to care also had little effect on
the results. Higher rates of test offer/accept and linkage to care
improved survival and increased costs, but had little impact on
cost-effectiveness.
Discussion
The Revised National TB Control Programme in India currently
recommendsreferral for voluntaryHIV counselingand testing of all
TB patients in the nine highest HIV prevalence states, with risk-
basedreferralelsewhere[7].Whilefullimplementationofthispolicy
would make major progress in HIV case identification, it is still a
Table 6. Incremental cost-effectiveness of alternative HIV testing strategies for TB patients in India.
Strategy
Discounted mean
per-person life expectancy,
years (undiscounted)*
Discounted mean
per-person lifetime
costs (undiscounted)**
Cost-effectiveness
ratio, $/YLS
Strategy 1: Selective referral of high-risk patients 16.88 (28.90) 100 (135) —
Strategy 2: HIV testing for all TB patients in the nine highest HIV
prevalence states
16.90 (28.92) 110 (150) 650
Strategy 3: Routine referral for HIV testing for all TB patients 16.91 (28.93) 120 (160) 730
YLS: Year of life saved.
*Life expectancy beginning at age 33.50 (see Methods).
**Costs are in 2008 US$.
doi:10.1371/journal.pone.0012747.t006
Figure 1. Sensitivity analysis on HIV prevalence among TB patients. The cost-effectiveness of routine referral for HIV testing for all TB
patients (Strategy 3) compared to the current standard of referral for HIV testing for TB patients in the nine states with the highest HIV prevalence
and selective referral elsewhere (Strategy 2), as a function of HIV prevalence and HIV test cost. The 3x and 1x per capita GDP for India represent
thresholds for ‘‘cost-effective’’ and ‘‘very cost-effective’’ health care interventions, as recommended by the WHO (See Methods). GDP: Gross Domestic
Product; YLS: Year of life saved.
doi:10.1371/journal.pone.0012747.g001
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patients who could also benefit from HIV testing and ART. Using a
detailed simulation model of HIV and TB disease, we found that a
strategy of routinereferral for HIVtesting in all TB patients inIndia
compared to HIV testing referral in only the nine highest HIV
prevalence states (the current standard) may lead to substantial
individual survival benefits. HIV-infected TB patients who were
treated for HIV disease had an undiscounted per-person mean life
expectancy increase of 5.83 years compared to those not treated for
HIV, regardless of TB outcome. For those who remained in TB
care, and were cured of TB, referral for HIV testing and linkage to
care had the greatest impact on survival. Patients cured of TB who
linked to care and received ART had an undiscounted mean life
expectancy of 13.87 years, or an increase of 9.16 years over those
cured of TB but not treated for HIV.
Referral for HIV testing of all TB patients in India compared to
HIV testing referral in only the nine highest HIV prevalence states
had an incremental cost-effectiveness ratio of $730/YLS. Routine
referral for HIV testing of all TB patients in India would be
considered very cost-effective (cost-effectiveness ratio ,1x per capita
GDP) [20].Infact,NACO and the RNTCPhaverecently proposed
routine HIV counseling and testing for all TB patients nationwide
by 2012. The current study supports this policy decision and
highlights that the policy will be very cost-effective. Our findings
also support the current WHO recommendation of routine referral
for HIV testing for TB patients in all settings [40]. Our analysis
examined HIV testing referral for TB patients, so an analysis of
screening HIV-infected patients for TB or of cross-referral services
would provide additional important policy information.
In 2009, NACO and the RNTCP revised the ‘‘National
Framework for Joint TB/HIV Collaborative Activities’’ to
strengthen NACO and RNTCP coordination, as well as
coordination between HIV counseling and testing centers and
ART centers [11]. The revised framework also establishes
mechanisms for better reporting, monitoring, and evaluation of
the programs, and provides additional training on TB and HIV for
staff. A commitment to screen for HIV infection must be coupled
with a commitment to HIV care. Although ART scale-up has led
to 272 treatment centers and 10 Regional Centers of Excellence
nationally, with integrated counseling and testing services available
in every district in India, whether they would be able to
accommodate the increased patient burden resulting from routine
HIV testing referral is unclear [41]. Successfully implementing a
routine HIV testing referral program for the approximately 1.8
million people starting TB treatment each year in India will
require a major commitment. One recent pilot study of routine
referral for HIV testing in India found that patients identified as
HIV-infected had low rates of ART initiation, even when they met
immunological starting criteria [19]. Further expansion and
decentralization of HIV diagnostic and treatment services is
underway to prepare for the expanded implementation of the
Intensified TB/HIV Package and to provide access to HIV
services closer to patients’ homes [11,19].
Routine testing can detect HIV infection among individuals in
an earlier disease stage, before their CD4 count falls to low levels
associated with high morbidity and mortality. Currently, 85% of
people living with HIV and registered for ART in India registered
when their CD4 count was already ,250/ml [42]. With earlier
HIV diagnosis, patients can initiate ART at higher CD4 counts,
and prevent much of the morbidity and mortality that occurs in
lower CD4 strata [17]. TB morbidity and mortality in India is a
major driver of global TB outcomes, given the size of India’s
population. The Millennium Development Goals include halving
TB prevalence and death rates between 1990 and 2015. Reducing
mortality among HIV-infected TB patients has been identified as
an important target for India to reach the Millennium Develop-
ment Goals; identifying and treating HIV-infected TB patients
with ART could contribute substantially toward reaching this
target [43]. ART has also been demonstrated to reduce the risk of
TB for HIV-infected patients, by lowering HIV RNA levels and
increasing CD4 counts [44,45]. However, in order for the clinical
benefits and cost-effectiveness of routine HIV testing to be
realized, linkage to HIV care and treatment must be maximized
[46]. One potential strategy to maximize patient retention
between the TB center and HIV counseling and testing center
would be to integrate HIV testing and treatment into TB services.
The results of this analysis were robust across a wide range of
sensitivity analyses. Results depended on HIV prevalence, but the
policy implications did not change unless the prevalence was
substantially below that reported anywhere in India [10]. Neither
outcomes nor cost from TB or HIV disease, including TB-related
mortality rates, had a major impact on the results. Even
decentralized HIV testing in India, in areas with relatively low
HIV prevalence, will be both effective and cost-effective. Since
HIV is common in patients with TB, routine referral for voluntary
HIV testing of all TB patients will lead to substantial survival
benefits, since effective HIV treatment is now widely available in
India [24]. Even if the likelihood of patients linking to HIV care
was decreased by 40% with routine referral, HIV testing of all
patients remained very cost-effective. Although lower linkage rates
did adversely affect survival, the impact of linkage on cost-
effectiveness is minimal, because as fewer people link to HIV care,
both costs and survival decrease. The cost of second-line ART had
an impact on the cost-effectiveness of HIV testing, since the cost-
effectiveness is highly dependent on the lifetime cost of HIV care,
which in turn depends crucially on the cost of second-line therapy.
If second-line ART was not available, the survival benefits of HIV
testing were less, but the cost-effectiveness results were robust.
HIV testing of TB patients may also confer further benefits in
India through its impact on HIV prevention. Although not directly
evaluated in the current study, many studies from resource-limited
settings have shown that patients testing positive for HIV
significantly decrease high-risk behaviors [47,48,49,50,51]. The
impact of testing negative for HIV on risk-taking behavior is less
clear [49]. However, evidence suggests that HIV testing and
referral programs will improve HIV prevention, with benefits
extending beyond the individual survival benefits highlighted in
the current analysis.
The other highest TB burden countries in the world—China,
Indonesia, Nigeria, and South Africa—had estimated HIV
prevalence in incident TB cases for 2008 ranging from 2.8%
(Indonesia) to 71% (South Africa). However, only 22% of TB
patients worldwide were tested for HIV in 2008 [52]. Because
providing ART is essential to decreasing mortality from TB for
HIV-infected persons, detecting HIV earlier, through routine
referral for HIV testing for all patients receiving TB treatment, will
substantially increase their survival, and likely be cost-effective in
other high TB burden countries. HIV testing and earlier initiation
of ART may also have prevention benefits by decreasing HIV
transmission [50,51,53].
There are several limitations to this study. First, data on long-
term outcomes for HIV-infected patients cured from TB disease
remain scarce. We used the best available data and conducted both
univariate and multivariate sensitivity analyses to test the robustness
of the results given this uncertainty. While probabilistic sensitivity
analysis to simultaneously address uncertainty among all input
parameters would be additionally informative, this was not feasible
in this Monte Carlo microsimulation. We also assumed in the base
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care, regardless of disease stage. We did not include the additional
benefits of decreasing both HIV transmission and TB transmission
by identifying, counseling, and treating HIV disease in TB patients
[48,50,53,54,55]. Including these benefits would render routine
HIV testing even more cost-effective [53]. We also did not include
disability-adjusted life years (DALYs) in the analysis. Even for those
who do not die from TB, the disease may result in substantial
disability [56]. Thus, if DALYs were included in the analysis,
routine HIV testing might be evenmore cost-effective. We also used
HIV natural history data from a private clinic in Chennai rather
than from government facilities. However, since the main
determinant of the cost-effectiveness results is HIV prevalence,
these results are likely generalizable to other regions of India. While
the new WHO recommendations include ART for any HIV-
infected patient with TB, regardless of CD4 count, in this analysis
only patients with CD4,350/ml were treated with ART [57]. Since
allpatientsinthisanalysishadactiveTB,wedidnotincludethenew
WHO recommendation for isoniazid preventive therapy in patients
with HIV in whom TB disease is excluded [58].
Among people with HIV infection in India, TB is the most
common opportunistic infection and cause of death [1,27].
However, the majority of TB patients are not tested for HIV.
Our findings suggest that in a country with low overall HIV
prevalence, routine voluntary HIV testing of all TB patients would
be both clinically effective and very cost-effective. The intersection
of the dual epidemics of HIV and TB requires effective HIV and
TB case detection and linkage to care to ensure the best possible
outcomes for co-infected individuals. Routine voluntary HIV
testing for all TB patients in India should be widely implemented.
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